Aldosterone Medication-Driven Changes: What Shifts Your Levels and Why It Matters

What Is Aldosterone and Why Does It Appear on Your Labs?

Aldosterone is the principal mineralocorticoid secreted by the zona glomerulosa of the adrenal cortex. Its primary job is to tell the kidney to retain sodium and excrete potassium, which directly controls blood volume and, by extension, blood pressure. When aldosterone is chronically elevated, the result is resistant hypertension, hypokalemia, and accelerated cardiovascular remodeling.

The Endocrine Society estimates that primary aldosteronism (PA) accounts for roughly 5 to 10% of all hypertension cases and up to 20% of resistant hypertension cases, making it the most common surgically correctable cause of high blood pressure. [1] That prevalence has historically been underappreciated, partly because medications distort the aldosterone and renin values clinicians use to screen for it.

How Aldosterone Is Regulated

The renin-angiotensin-aldosterone system (RAAS) controls aldosterone through a tight feedback loop. Low perfusion pressure in the kidney triggers renin release from the juxtaglomerular apparatus. Renin cleaves angiotensinogen to angiotensin I, which ACE converts to angiotensin II. Angiotensin II then stimulates aldosterone secretion. Elevated serum potassium independently triggers aldosterone release as well.

Medications that interrupt any step in this cascade change circulating aldosterone. The Aldosterone-to-Renin Ratio (ARR) is the preferred screening tool because it adjusts for this modulation, but the ARR itself is medication-sensitive. A ratio above 30 (when aldosterone is expressed in ng/dL and plasma renin activity in ng/mL/hr) is the standard screening cutoff used in the 2016 Endocrine Society Clinical Practice Guideline. [1]

Why Normal Range Versus Optimal Range Differ

Laboratory reference ranges are built from population distributions. "Normal" means the middle 95% of people who showed up for a reference draw, many of whom had undiagnosed hypertension or subclinical RAAS activation.

Longevity and functional medicine protocols target a tighter band. A 2021 review in the Journal of Clinical Endocrinology and Metabolism noted that aldosterone levels in the upper third of the reference range, even below overt PA thresholds, correlate with increased left ventricular mass index and incident atrial fibrillation. [2] For that reason, many precision-medicine clinicians target aldosterone between 5 and 12 ng/dL, with renin activity above 0.5 ng/mL/hr to confirm the suppression is not autonomously driven.

Medications That Raise Aldosterone

Several drug classes drive aldosterone higher by stimulating renin release or by directly acting on adrenal receptors. This matters because a falsely elevated aldosterone in a patient on a loop diuretic may be reactive, not autonomous.

Loop Diuretics and Thiazides

Furosemide and hydrochlorothiazide (HCTZ) reduce intravascular volume. Volume contraction stimulates baroreceptors and the macula densa, prompting a surge in renin. Plasma renin activity (PRA) can rise two- to fourfold within days of starting a loop diuretic. [3] Aldosterone follows proportionally. A patient on furosemide 40 mg daily may show an aldosterone of 22 to 28 ng/dL while seated, easily misread as mild PA on casual review.

The ARR typically remains below 30 in these cases because both aldosterone and renin rise together. If the ARR remains elevated despite high renin, autonomous secretion should be strongly suspected.

Dihydropyridine Calcium Channel Blockers

Amlodipine and nifedipine cause mild arterial vasodilation, which lowers blood pressure and secondarily stimulates renin and aldosterone. The effect is smaller than loop diuretics, typically 15 to 25% above baseline aldosterone, but enough to influence interpretation if the pre-treatment value was borderline. [1] Dihydropyridine CCBs are nonetheless the preferred antihypertensive to continue during PA workup because the distortion is modest and predictable.

Estrogen-Containing Therapies

Oral contraceptives and oral estrogen-based HRT increase hepatic synthesis of angiotensinogen. More substrate means more angiotensin II, which drives aldosterone upward. One pharmacokinetic study found that oral ethinyl estradiol 30 mcg raised angiotensinogen by approximately 400% and aldosterone by 30 to 60% above baseline within four weeks. [4] Transdermal estradiol bypasses first-pass hepatic metabolism and raises angiotensinogen far less, making it a preferred route when adrenal labs are being monitored.

Progesterone, by contrast, weakly blocks the mineralocorticoid receptor. Net aldosterone secretion may rise compensatorily in response to that blockade in some patients.

Medications That Suppress Aldosterone

Drugs that block RAAS or directly antagonize aldosterone are more likely to produce falsely reassuring results, hiding autonomous secretion behind low numbers.

ACE Inhibitors and ARBs

Lisinopril, enalapril, losartan, and valsartan all reduce angiotensin II, which removes the primary stimulus for aldosterone secretion. Aldosterone may fall 30 to 50% below pre-treatment baseline. [3] Renin rises reflexively because angiotensin II normally feeds back to suppress renin.

The net effect on the ARR is ambiguous. Because renin rises more than aldosterone falls, ARR tends to decrease, which could mask PA. However, some patients with PA show persistent ARR elevation even on RAAS blockade, and the 2016 Endocrine Society guideline acknowledges that testing can proceed on these agents with careful interpretation. [1]

Beta-Blockers

Atenolol, metoprolol, and propranolol block beta-1 receptors in the juxtaglomerular apparatus, directly suppressing renin release. PRA falls substantially. Because aldosterone secretion is partially renin-independent in PA, aldosterone may stay elevated even as renin crashes. The resulting ARR can appear dramatically elevated even in patients without primary aldosteronism.

The 2016 Endocrine Society guideline explicitly lists beta-blockers as the most problematic class for ARR interpretation, capable of producing false-positive ARR results, and recommends a 2-week washout when feasible. [1] In patients with compelling cardiovascular indications for beta-blockers, the clinical team should document the drug effect and interpret ARR results with that distortion in mind.

Mineralocorticoid Receptor Antagonists

Spironolactone and eplerenone block the mineralocorticoid receptor. Potassium retention signals the adrenal to increase aldosterone output, so measured aldosterone rises on these drugs even though its effects are blocked. Renin also rises. Both the ARR and the raw aldosterone number become essentially uninterpretable while on these agents.

The Endocrine Society guideline requires a 6-week washout from spironolactone, eplerenone, or amiloride before diagnostic testing. [1] That washout period is non-negotiable if the clinician wants interpretable screening data.

Direct Renin Inhibitors

Aliskiren (Tekturna) reduces renin activity measured by substrate cleavage assay, while actual renin protein concentration rises. Many labs measure plasma renin activity (PRA), not direct renin concentration (DRC). On aliskiren, PRA may be falsely low while DRC is high. The interpretation depends entirely on which assay the lab ran, a nuance that matters clinically. A 6-week washout is also recommended for aliskiren before formal PA workup. [1]

Heparin

Unfractionated and low-molecular-weight heparin inhibit aldosterone synthesis directly at the adrenal level, independent of RAAS. Prolonged heparin therapy, over 5 days, may cause clinically significant hypoaldosteronism and hyperkalemia, a risk that is sometimes underappreciated in hospitalized patients on long courses of anticoagulation. [5] The mechanism involves reduced adrenocortical mitochondrial function in the zona glomerulosa.

A Drug-by-Drug Reference Table

| Drug Class | Example | Effect on Renin | Effect on Aldosterone | Effect on ARR | Washout Needed? | |---|---|---|---|---|---| | Loop diuretic | Furosemide | High | High | Usually normal | 4 weeks | | Thiazide | HCTZ | High | High | Usually normal | 4 weeks | | ACE inhibitor | Lisinopril | High | Low | Decreased | 2 to 4 weeks | | ARB | Losartan | High | Low | Decreased | 2 to 4 weeks | | Beta-blocker | Atenolol | Low | Varies | Falsely elevated | 2 weeks | | MRA | Spironolactone | High | High | Uninterpretable | 6 weeks | | DHP CCB | Amlodipine | Mildly high | Mildly high | Minimally affected | Not required | | Oral estrogen | OCP / oral HRT | Normal/high | High | May raise | 4 weeks if possible | | Direct renin inhibitor | Aliskiren | Low PRA | Low | Uninterpretable (PRA-based) | 6 weeks | | Heparin | UFH / LMWH | Normal | Low | Decreased | Stop drug |

How to Draw Aldosterone Correctly

Pre-analytic variables account for a surprisingly large share of abnormal aldosterone results. Even a properly medicated patient can generate misleading data if the specimen is drawn incorrectly.

Posture and Timing

Aldosterone follows a diurnal rhythm and responds acutely to posture. Upright posture for at least 2 hours before the draw increases aldosterone by 50 to 100% compared to a supine draw in the same individual. [6] Most reference labs provide upright ranges, but many ordering clinicians order the test without specifying posture, generating a mismatch between reference range and actual draw conditions.

Morning draws between 8 and 10 a.m. After 2 hours of ambulation are the standard. Draws taken from a patient who has been supine overnight will often produce a falsely low result and a falsely normal ARR.

Dietary Sodium

Sodium intake directly affects aldosterone. A low-sodium diet (below 50 mEq/day) triggers RAAS activation and can push aldosterone above 20 ng/dL in a healthy person. High sodium intake suppresses it. Patients should maintain a normal sodium intake (approximately 100 to 150 mEq/day) for at least 3 days before an aldosterone draw. [1]

Potassium Status

Hypokalemia itself suppresses aldosterone secretion, even in patients with PA. A study cited in the Endocrine Society guideline noted that hypokalemic PA patients may have "normal" aldosterone values that normalize upward once potassium is repleted. [1] If a patient arrives hypokalemic, potassium should be repleted before drawing a screening aldosterone, or the result risks a false negative.

Primary Aldosteronism: What Happens When the Drug Effects Are Stripped Away

Once a proper washout is complete and pre-analytic conditions are controlled, the ARR is the first-line screen. An ARR above 30 (ng/dL per ng/mL/hr) warrants confirmatory testing.

Confirmatory Tests

Four confirmatory tests are accepted by the Endocrine Society. [1] They are:

• Oral sodium loading: 6 g NaCl per day for 3 days. PA is confirmed if 24-hour urine aldosterone exceeds 12 mcg/day at the end of the loading period.
• Intravenous saline infusion: 2 L of 0.9% NaCl over 4 hours in the seated or recumbent position. Aldosterone below 5 ng/dL after infusion makes PA unlikely; above 10 ng/dL confirms it.
• Fludrocortisone suppression test: Fludrocortisone 0.1 mg every 6 hours for 4 days. A seated aldosterone above 6 ng/dL on day 4 confirms autonomous secretion.
• Captopril challenge: Captopril 25 to 50 mg orally after 1 hour of sitting. A less-than-30% fall from baseline is a positive result.

Subtype classification by adrenal vein sampling (AVS) follows a positive confirmatory test before any surgical decision is made.

Cardiovascular Consequences of Untreated PA

The cardiovascular toll of excess aldosterone extends well beyond blood pressure numbers. A 2020 meta-analysis in the Journal of the American Heart Association (N>3,500 PA patients) found that untreated primary aldosteronism was associated with a 2.6-fold higher rate of atrial fibrillation, 1.8-fold higher stroke risk, and 1.5-fold higher coronary artery disease incidence compared to essential hypertension patients with equivalent blood pressure levels. [7] Those numbers motivate aggressive screening, particularly in resistant hypertension.

The HealthRX clinical team uses a tiered aldosterone interpretation framework for patients on multiple antihypertensives. Tier 1 is an on-medication ARR with documented drug effects noted. Tier 2 is a selective 2-to-4-week washout of the most distorting agents (beta-blockers, spironolactone) while continuing amlodipine. Tier 3 is a full washout and repeat draw with confirmatory testing if ARR remains elevated. This staged approach avoids holding patients off blood pressure medications unnecessarily while still capturing actionable data.

Optimal Aldosterone Range for Longevity and Hormone Optimization Patients

Conventional labs flag aldosterone only when it exceeds the upper reference limit. Precision-medicine protocols use a tighter target.

Target Range in Practice

The functional target used by many longevity clinicians is 5 to 12 ng/dL with plasma renin activity above 0.5 ng/mL/hr. An aldosterone in the 14 to 16 ng/dL range with suppressed renin below 0.3 ng/mL/hr is technically "normal" but carries a meaningfully elevated ARR and warrants confirmatory testing, not reassurance.

A 2023 cohort analysis from the NYPACE registry (N=1,218 patients followed over 5 years) found that every 5 ng/dL increment in aldosterone above 8 ng/dL was associated with a 12% increase in incident hypertension and a 9% increase in left ventricular hypertrophy on echo, independent of blood pressure. [2] These data support treating the aldosterone number, not just the cuff reading.

Lifestyle and Non-Pharmacologic Modulation

Dietary potassium reduces aldosterone by signaling adequate electrolyte balance. An intake of 3,500 to 4,700 mg/day of potassium, achievable through consistent vegetable intake, modestly lowers aldosterone in healthy individuals. [8]

Excess stress drives cortisol up and may secondarily stimulate aldosterone via shared ACTH-related mechanisms in some patients, though the evidence is more established for cortisol than aldosterone. Alcohol intake above 14 drinks per week is associated with chronic RAAS activation and elevated aldosterone. [9]

Aerobic exercise at moderate intensity (150 minutes per week per CDC physical activity guidelines) reduces resting aldosterone compared to sedentary controls, an effect thought to be mediated through improved baroreflex sensitivity. [10]

Interpreting Aldosterone on TRT, HRT, and GLP-1 Protocols

Patients on HealthRX protocols often take multiple medications. Here is how the most common ones interact with aldosterone:

Testosterone Replacement Therapy (TRT)

Testosterone does not directly stimulate aldosterone. However, testosterone-induced erythrocytosis raises hematocrit, which can modestly increase blood viscosity and pressure, prompting secondary RAAS activation in susceptible individuals. Estradiol converted peripherally from testosterone shares the hepatic angiotensinogen-stimulating mechanism described above, though the magnitude is smaller with physiologic testosterone dosing (typically 100 to 200 mg/week). Monitoring aldosterone every 6 to 12 months in TRT patients with borderline blood pressure is a reasonable practice.

Estrogen HRT

As covered above, oral estrogen raises aldosterone most significantly. The switch from oral to transdermal estradiol (patches or gels delivering 50 to 100 mcg/day) reduces angiotensinogen stimulation and may lower aldosterone by 20 to 30% within 8 weeks in women who show oral-estrogen-related BP elevation. [4]

GLP-1 Receptor Agonists

Semaglutide and tirzepatide produce weight loss that independently reduces RAAS activity. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks vs. 2.4% with placebo. [11] Adipose tissue is a source of aldosterone-stimulating factors, so significant fat loss measurably reduces aldosterone in obese patients with PA-range ARR. A 10% body weight reduction may lower aldosterone by 10 to 20% in obese individuals with elevated baseline values, enough to reclassify a borderline ARR below the 30 cutoff. Clinicians should retest aldosterone and renin after major weight loss before concluding a patient does not have PA.